Sign inJoin waitlistJoin the waitlist

SS

Stephen Spurgeon

Professor of Medicine, School of Medicine · Oregon Health & Science University

Credentials: · · ·

History

Oregon Health & Science University
Present

Oregon Health & Science University
2006–2009
Internal Medicine
Oregon Health & Science University
2002–2005
Sidney Kimmel Medical College at Thomas Jefferson University
1998–2002
Bowdoin College
1994–1998

Research

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
New England Journal of Medicine · 2013 · 1,377 citations
Functional genomic landscape of acute myeloid leukaemia
Nature · 2018 · 1,111 citations
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Blood · 2014 · 545 citations

AD
Alexey Danilov
21 papers
ML
Marc Loriaux
12 papers
Brian Druker
10 papers
BK
Brad Kahl
9 papers
JB
John Byrd
8 papers
Adam Kittai
7 papers · 1 as a fellow
CO
Craig Okada
7 papers
Deborah Stephens
6 papers
Guang Fan
6 papers
IF
Ian Flinn
6 papers
Jennifer Brown
6 papers
MK
Myung Kim
6 papers

Clinical trials

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
Principal investigator · Recruiting · Phase 2
OHSU Knight Cancer Institute
2025–2027
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
Principal investigator · Recruiting · Phase 1, Phase 2
OHSU Knight Cancer Institute
2025–2029
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Principal investigator · Recruiting · Phase 1, Phase 2
OHSU Knight Cancer Institute
2024–2027
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Principal investigator · Recruiting · Phase 1
OHSU Knight Cancer Institute
2023–2028